Clinical Chemistry Markers in ALS and Their Impact on Survival
Author Information
Author(s): Psychogios Ioannis, Hu Yihan, Seitz Christina, Joyce Emily E., Lovik Anikó, Ingre Caroline, Fang Fang
Primary Institution: Karolinska Institutet, Stockholm, Sweden
Hypothesis
Commonly measured clinical chemistry markers might be indicative of survival and disease progression in amyotrophic lateral sclerosis (ALS).
Conclusion
Clinical chemistry markers, including NfL, lipids, albumin, leukocyte count, MCV, MCH, and CO2, were associated with ALS survival.
Supporting Evidence
- Higher levels of total cholesterol and LDL-C at diagnosis were linked to lower mortality in ALS patients.
- Increased levels of neurofilament light chain and leukocyte count indicated higher mortality.
- The 'Red blood cell profile' factor was a significant predictor of survival.
Takeaway
Doctors can look at certain blood tests to help understand how long someone with ALS might live and how their disease will progress.
Methodology
A cohort study examined the link between 29 clinical chemistry markers at diagnosis and mortality risk at 6 months, 1 year, and 3 years after diagnosis.
Potential Biases
Potential biases due to missing data and variations in the number of biomarker measurements among patients.
Limitations
The study may have limited statistical power for small effect sizes and did not apply correction for multiple testing in exploratory analyses.
Participant Demographics
Mean age at diagnosis was 66 years, with a nearly equal ratio of men to women and about one third having bulbar onset.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI varies by marker
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website